. Author manuscript; available in PMC: 2013 Sep 15.

Published in final edited form as: Leukemia. 2013 Mar 21;27(8):1738–1744. doi: 10.1038/leu.2013.86

Table 3.

Cytogenetically defined risk-based classification of SMM

Risk	Cytogenetic class	No. of patients (%)^a	Median TTP to myeloma (months)^*	Median TTP to myeloma or related disorder (months)^**	Median OS from SMM diagnosis (months)^***	Median OS from MM diagnosis (months)^****,^b
High-risk^a	t(4;14), del(17p)	44 (12.5%)	24	24	105	60
Intermediate- risk	Trisomy (ies) without IgH translocation	148 (42.2%)	34	34	135	77
Standard-risk	t(11;14) MAF translocations, t14;16 or t(14;20) Other/unknown IgH translocation partner Both trisomies and IgH translocation except t(4;14) Monosomy13/del(13q) in absence of IgH translocation or trisomies	106 (30.2%)	55	54	147	86
Low-risk	No abnormalities (normal or insufficient)	53 (15.1%)	Not reached	101	135	112

Abbreviations: IgH, immunoglobulin heavy chain; MAF, musculoaponeurotic fibrosarcoma; MM, multiple myeloma; OS, overall survival; SMM, smoldering multiple myeloma; TTP, time to progression.

P = 0.001.

^**

P = 0.002.

^***

P = 0.12 (global); P = 0.02 (high-risk versus standard-risk).

^****

P = 0.04.

Modified to include del(17p) and t(4;14) with concurrent trisomies.

N = 219 patients.